Consistently, pharmacological inhibition of VEGFR markedly reduced VEGFR-2+ cell population in GBM ECs but not in normal ECs, suggesting more robust anti-VEGF resistance in VEGFR-2− GBM ECs (Supplementary Fig. 2), compared to VEGFR-2+ ECs. This evidence concerns the gene VEGFA and glioblastoma.